



August 13, 2021 *(Updated September 1, 2021)*

Web Announcement 2559

Provider Billing Guidance for Synagis® (Palivizumab)

Nevada Medicaid (Fee-for Service/Check Up) is providing updated guidance for billing Synagis® (palivizumab). Providers must submit requests for the number of required whole vials. Requests for partial vials will be rejected with messaging from the pharmacy system indicating missing or invalid quantity. Please refer to the following table for dosing allowance for calculating dosage and number of required vials.

Dosing Allowance: Synagis® is available only in 50mg and 100mg vials. Due to the potential for significant waste, the following table should be utilized to determine permitted dose (within 10% of calculated dose due to vial overfill) and vials to dispense.

Weight-based Dose	Range Vial Quantity Recommendation
≤ 52.49 mg	1 vial of 50 mg/0.5 mL
52.5 mg – 104.99 mg	1 vial of 100 mg/1 mL
105 mg – 157.49 mg	1 vial of 50 mg/0.5 mL and 1 vial of 100 mg/1 mL
157.5 mg – 209.99 mg	2 vials of 100 mg/1 mL
210 mg – 262.49 mg	1 vial of 50 mg/0.5 mL and 2 vials of 100 mg/1 mL
262.5 mg – 314.99 mg	3 vials of 100 mg/1 mL

Due to atypically high levels of circulating Respiratory Syncytial Virus (RSV), Nevada Medicaid will open the Synagis® coverage season on September 1, 2021. Effective immediately, Nevada Medicaid providers may submit prior authorization (PA) requests for Synagis® (palivizumab). Providers may submit claims for approved Synagis® PAs beginning September 1, 2021. Reimbursement is only authorized during the 2021-2022 Nevada RSV season from September 1, 2021, through March 31, 2022. RSV activity will be closely monitored during the seven-month time frame to determine if the season length should be adjusted.

The clinical criteria used by Nevada Medicaid for the 2021-2022 RSV season are consistent with guidance published by the American Academy of Pediatrics (AAP): 2021 – 2024 Report of the Committee on Infectious Diseases, 32nd Edition. This guidance for Synagis® use among infants and children at increased risk of hospitalization for RSV infection is available online by subscription. Providers are encouraged to review the AAP guidance.

The [Synagis® Authorization Request Form \(FA-65\)](#) has been updated for the September 1, 2021, through March 31, 2022, RSV season. The [Pharmacy Billing Manual](#) has been updated with Synagis® claim submission instructions.

For any questions, call the OptumRx Call Center for Nevada Medicaid at (855) 455-3311.